Clinical Trial

A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A phase 2b, randomized, placebo-controlled study with long-term re-treatment to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-20.
Trial Details
NCT Number NCT07608757
Lead Sponsor Caliway Biopharmaceuticals Co., Ltd.
Conditions Subcutaneous Fat
Enrollment 250 participants
Start Date 2027-02
Primary Completion 2028-02 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-29